Dominik Heinzmann

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 501 citations

Medicine, Oncology, Breast Oncology +13

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Aňa Lluch et al. · The Lancet Oncology · 2014 · 491 citations

Medicine, Oncology, Breast Oncology +16

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer et al. · The Lancet Oncology · 2012 · 346 citations

Medicine, Oncology, Pharmacology +17

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Marion van Mackelenbergh, Sibylle Loibl, Michael Untch et al. · Journal of Clinical Oncology · 2023 · 96 citations

Medicine, Oncology, Breast Oncology +16

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy et al. · European Journal of Cancer · 2016 · 78 citations · Full text

Medicine, Oncology, Pharmacology +12